AMEA

Easy-to-interpret report for MRD detection and recurrence monitoring with a simple blood draw.

ctDNA, circulating tumor DNA; MRD, minimal residual disease.

Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.